Core Framework & Diagram Inflammatory Bowel Disease
July 28, 20261 Min Read Can Autoimmunity Reverse?
July 28, 2026Always have an unsettled stomach? One disease makes your immune system treat your intestines as a battlefield
—— IBD: the immune nature of Crohn's disease and ulcerative colitis.
I. Two diseases, one root, different 'battlefields'
IBD primarily includes two types. Ulcerative colitis (UC) — inflammation limited to the colonic mucosa layer, starting from the rectum and potentially spreading upward but not crossing the ileocecal valve into the small intestine. The inflammation is continuous and doesn't skip normal intestinal segments. Primary symptoms: diarrhea (often with pus and blood), urgency, abdominal pain.
Crohn's disease (CD) — can affect any part of the digestive tract from mouth to anus, most commonly the terminal ileum and colon. Its inflammation penetrates the full thickness of the intestinal wall, can form fistulas (abnormal passages between intestines or between intestine and skin), abscesses, and intestinal strictures. Primary symptoms: abdominal pain, diarrhea (usually without blood or less blood), weight loss, fatigue.
Both are lifelong diseases with the typical disease course of alternating 'remission-relapse.' During remission, patients may be almost indistinguishable from healthy people; during relapse, they may be severely debilitated, unable to live and work normally.
2. Why does the gut immune system attack its own commensal bacteria?
Normally, the gut is where immune system and bacteria coexist most densely. Healthy gut immunity is in an exquisitely balanced state: vigilant against pathogens, tolerant toward commensal bacteria. In IBD patients, this balance is disrupted. Multiple factors work together: genetics (over 240 genetic risk loci identified, many related to immune cell signal transduction, barrier function, and bacterial recognition; NOD2 gene variants are among the earliest confirmed Crohn's disease genetic risk factors); gut microbiome dysbiosis (IBD patients' gut microbiome diversity is significantly reduced, beneficial bacteria producing short-chain fatty acids decrease, while some inflammatory bacteria proportions rise); gut barrier function defects; and environmental factors (Western diet, antibiotic use, caesarean delivery, urban lifestyle).
3. IBD's rapid rise in Asia: a trend worth heeding
IBD was once considered primarily a disease of Western Caucasians. This perception has been completely overturned by epidemiological data from the past twenty years. Asia — including China, Japan, Korea, India, Malaysia — saw IBD incidence begin rapidly rising after 2000, at rates even exceeding Western countries. China's IBD case count growth has been particularly significant, transforming from a rare disease into a common chronic disease requiring specialty center management.
This trend is believed closely related to Asia's rapid urbanization, dietary Westernization (sharply increased refined sugars and ultra-processed foods, sharply decreased dietary fiber), and widespread antibiotic use. For middle-aged Asian populations, understanding IBD's early symptoms (persistent diarrhea, abdominal pain, unexplained weight loss, bloody stool), and seeking medical care promptly rather than self-diagnosing as 'gastroenteritis,' may significantly shorten diagnostic delays — IBD's average diagnostic delay in Asia is still over one to three years.
4. Extra-intestinal manifestations: IBD's effects hidden outside the intestines
Approximately twenty-five to forty percent of IBD patients develop at least one extra-intestinal manifestation — the most direct proof of IBD as a systemic disease. Most common extra-intestinal manifestations include: arthritis (the most common extra-intestinal manifestation, divided into peripheral arthritis paralleling intestinal activity and axial arthritis independent of intestinal activity); skin lesions (erythema nodosum and pyoderma gangrenosum are the two most characteristic skin manifestations); ocular inflammation (iritis, uveitis, which can precede intestinal symptoms); and primary sclerosing cholangitis (PSC, a chronic inflammatory injury of the bile ducts closely associated with ulcerative colitis, one of IBD's most serious extra-intestinal manifestations).
These extra-intestinal manifestations suggest IBD's immune dysregulation isn't limited to the gut but affects multiple organs at the systemic level. Some manifestations are closely related to intestinal inflammatory activity (when gut improves they improve too), while others evolve independently requiring separate treatment. This complexity is why IBD patients need multi-specialty coordinated management rather than just gastroenterology single-specialty follow-up.
5. Treatment advances: from steroids to targeted biologics to small molecules
IBD treatment has experienced several major upgrades over the past twenty years. First-generation effective treatment was 5-aminosalicylic acid drugs (mesalamine, etc.), primarily for mild-to-moderate UC. Steroids were used for severe flares but can only be used short-term. In the early 2000s, anti-TNF-α biologics (infliximab, adalimumab) changed the treatment landscape for moderate-to-severe IBD.
Subsequently, biologic iteration introduced more selective targets: anti-integrin drugs (Vedolizumab, selectively blocking gut-specific immune cell migration, reducing systemic side effects); anti-IL-12/23 drugs (Ustekinumab); and the newest anti-IL-23 p19-specific drugs. Small-molecule oral drugs (JAK inhibitors, like Tofacitinib, Upadacitinib) provide an oral option, effective for both UC and CD. Treatment goals have also evolved: from 'symptom control' to 'mucosal healing' (endoscopically confirmed complete gut mucosal repair), to 'histological remission.'
6. Diet and IBD: not 'what can and can't be eaten'
IBD patients are frequently given various 'forbidden food lists.' In reality, no single diet has been proven to replace medication in controlling IBD, and no single food is universally problematic for all IBD patients. But some dietary directions have increasing evidence supporting their protective effects on gut microbiome and barrier function: high dietary fiber (may need briefly reduced fiber during active phases to reduce mechanical stimulation; during remission should aim to be diverse and high-fiber); fermented foods (help microbiome diversity); Mediterranean dietary pattern (associated with lower IBD patient relapse rates). Ultra-processed foods and emulsifiers have been found in animal experiments and human observational research to be associated with gut barrier disruption.
More importantly: IBD patients often have impaired nutrient absorption; malnutrition is an important factor affecting quality of life and immune function. Nutritionally, first ensure adequate total caloric and protein intake, then discuss what's better or worse. Patients with active Crohn's disease sometimes need enteral nutrition (providing complete nutritional formula via tube feeding) as auxiliary or replacement treatment, especially important in pediatric Crohn's disease.
7. IBD's psychological health and social function
IBD's 'invisible' nature creates unique psychological challenges for patients. Symptom unpredictability (diarrhea, abdominal pain, fecal incontinence) keeps patients continuously vigilant in social, travel, and work settings. Research shows approximately twenty-five percent of IBD patients have clinically significant depression; approximately thirty percent have anxiety disorder — these rates rise with disease activity level.
IBD patients in remission have quality of life not significantly different from healthy people; most can work, exercise, and have children normally. The main challenges are: disease unpredictability (not knowing when relapse will come), side effect management of some medications, and insufficient societal understanding of this 'invisible disease.' Effective disease management, psychological support, and patient mutual aid communities are comprehensive strategies for maintaining quality of life.
Frequently Asked Questions